Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials
Dinetz E, Lee E. Altern Ther Health Med. 2024; 30(1):6-12.
Summarises other people's work. Generates no new data.
Where this design sits
- Cells in a dish
- Animals
- Small human report
- Controlled human trial
- Pooled analysis
This is a review: it summarises other people's work and generates no new data, so it is not placed on the ladder.
- Who or what was studied
- Over 30 trials with more than 11,000 people, per the abstract
- Design
- Narrative review of trials in COVID-19, infections, cancer and autoimmune disease
What it found
The authors describe thymosin alpha-1 as well tolerated and effective across COVID-19, autoimmune disease and cancer, and argue that the FDA's 2023 restriction on compounding it is unfounded and should be reversed.
What it doesn’t show
The abstract reports no pooled numbers, trial-level results or assessment of bias, so its sweeping conclusion cannot be checked from the record. Lumping together trials of different diseases, doses and quality into one 'safety and efficacy' verdict hides results like the null sepsis and pancreatitis trials on this page. The paper ends with a regulatory recommendation, which is advocacy rather than a study result. PubMed tags it a systematic review, but the abstract calls it a narrative review.
Funding and conflicts of interest
No funding or conflict-of-interest statement appears in the PubMed record. Check the full text.
Claims we could not verify
That thymosin alpha-1 has 'consistent' efficacy across conditions, and that the FDA's restriction is 'unfounded'. The abstract gives no data behind either claim.
Summary written from the study's abstract and checked against PubMed on November 10, 2026. How we check studies. Educational information, not medical advice.
Related studies
- The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial (Wu et al., 2025)
- The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression (Soeroto et al., 2023)
- Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial (Ke et al., 2022)
- Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life (Wang et al., 2018)